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The Nevada Independent v. Whitley, 138 Nev. Adv. Op. 15 (Mar. 24, 2022)1
Trade Secrets: State District Court has Subject Matter Jurisdiction Over Fraudulent Conveyance
Actions
Summary:
The Nevada Supreme Court considered whether, under the Nevada Public Records Act
(NPRA), the federal Defend Trade Secrets Act (DTSA) prohibits disclosure of documents from
pharmaceutical companies and pharmacy benefit managers collected under S.B. 539. The Court
concluded that NAC 439.730-.740 are valid regulations and, the NPRA permits the
disclosure of government documents that are not declared by law to be confidential.2

Facts and Procedural History:
The DTSA, passed by Congress to compliment state trade secret laws, created a federal
cause of action for misappropriation of trade secrets and defined “misappropriation” to include
disclosure of a trade secret without the owner's consent, among other things.3 One year after the
DTSA was passed, the governor signed S.B. 539 into law in response to the rapidly increasing
price of insulin for Nevada residents.4 That bill was codified in NRS 439B.600-.695. The statute
requires pharmaceutical manufacturers and pharmacy benefit managers (PBMs) to submit to the
Department of Health and Human Services (DHHS) documentation regarding the cost structure
of insulin medication in Nevada. S.B. 539 requires PBMs to disclose the rebates they
negotiate, and DHHS to compile lists of essential diabetes medications, manufacturers to report
the pricing information of these drugs and justify any price increases.5 DHHS promulgated

regulations, NAC 439.730-.740, to harmonize S.B. 539, the NPRA, and the DTSA.
A reporter for The Nevada Inependent (TNI) later made a public records request to
DHHS for all reports submitted by pharmaceutical manufacturers and PBMs under S.B.
539. DHHS provided the names of manufacturers and PBMs and some general
information about the diabetes drugs but did not disclose other parts of the Manufacturer
Essential Diabetes Drug Reports, including (1) the cost of producing the drug, (2) the
total administrative expenditure relating to the drug, and (3) the profit margin the
manufacturer earned by producing the drug. DHHS argued that, pursuant to NAC
439.730- .740, disclosing this information would constitute misappropriating trade secrets
under the DTSA.
TNI filed a mandamus action in the district court to compel disclosure of the
requested information under the NPRA, and challenged the validity of NAC 439.7301
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.740. Sanofi-Aventis U.S. LLC, a pharmaceutical company that submitted records
pursuant to S.B. 539, moved to intervene. Sanofi submitted an affidavit from its Vice
President and Head of Diabetes and Primary Care Sales, James Borneman, who attested
to the precautions Sanofi implements to safeguard its trade secrets and the potential
economic hardship Sanofi would suffer from the trade secrets' disclosure.
The district court denied TNI’s writ petition. The district court determined that
"[t]he DTSA's definition for trade secrets places these reports squarely under
confidentiality protections," since DHHS demonstrated that the reports are subject to
reasonable efforts to maintain their secrecy and that the reports derive independent
economic value from such secrecy.6 Next, the district court found that NAC 439.730-.740
are valid regulations because DHHS has broad discretion to develop regulations that
"foster efficient enforcement of codified legislation" (in this case, S.B. 539) and DHHS
reasonably interpreted the governing statute in adopting the regulations. The district court
opined that these “regulations ensured that NPRA requests for information DHHS had
gathered due to S.B. 539 did not run afoul of the DTSA because, while the regulations'
‘confidentiality protections are not automatic,’ they ensured that the affected entity had
the opportunity to contest the release of what it believes to be confidential information in
court.”7 This appeal followed.
Discussion:
TNI has not demonstrated that NAC 439.730-.740 are invalid regulations
TNI argued that NAC 439.730-.740 are invalid regulations because they were not
authorized by the Nevada Legislature, and they conflict with S.B. 539. The Court denied all of
TNI’s arguments. The Court held that DHHS utilized the provision in NRS 439B.685, which
allows DHHS to adopt regulations it deems “necessary or advisable to carry out the provisions of
NRS 439B.600 to 439B.695, inclusive,” to promulgate NAC 439.735 and NAC 439.740 in order
to harmonize S.B. 539, the NPRA, and the DTSA.8
The Court “generally defers to an agency’s interpretation of a statute that the agency is
tasked with enforcing,9 but the regulation cannot contradict or conflict with the statute it is
intended to implement.10 Here, the Court found that NAC 439.735 does not contradict S.B. 539,
but instead creates a process by which DHHS can determine whether the requested records fall
within the DTSA’s protection of trade secrets. If DHHS does not believe that the requested
records require such protection, the burden then falls on the pharmaceutical company to
challenge DHHS’s finding in court. Therefore, it is not DHHS who makes the ultimate decision
regarding confidentiality, but a district court judge.
6

See 18 U.S.C. § 1839(3).
The Nev. Independent v. Whitley, 138 Nev. Adv. Op. 15 (Mar. 24, 2022).
8
NEV. REV. STAT. 439B.685.
9
State, Div. of Ins. v. State Farm Mut. Auto. Ins. Co., 116 Nev. 290, 293, 995 P.2d 482, 485 (2000).
10
Roberts v. State, 104 Nev. 33, 37, 752 P.2d 221, 223 (1988); accord Clark Cty. Social Serv. Dep't v. Newkirk, 106
Nev. 177, 179, 789 P.2d 227, 228 (1990).
7

TNI then argued that NAC 439.740 directly conflicts with the legislative intent in passing
S.B. 539. The Court held that the plain language of NRS 439B.650 is clear. It does not, as TNI
maintains, prohibit DHHS from anonymizing the data it collects per S.B. 539. Thus, NAC
439.740 does not conflict with NRS 439B.650, and DHHS had the authority to promulgate the
regulation under NRS 439B.685. Therefore, the Court concluded that TNIs challenge of NAC
439.740 fails and the regulation is valid.
The district court did not abuse its discretion by admitting James Borneman’s declaration
The DTSA classifies as trade secrets information (A) that the owner has taken
"reasonable measures" to keep secret and (B) from which the owner "derives independent
economic value" that is not "readily ascertainable through proper means by an entity that can
obtain economic benefit from the information's disclosure.11 "[T]he definition of what may be
considered a 'trade secret is broad."12 The government bears the burden of demonstrating by a
preponderance of the evidence that the public records at issue are confidential.13
The first element to determine whether information is a protected trade secret is whether
its owners have taken "reasonable measures" to keep the information secret.14 The Court
determined that the measures that manufacturers and PBMs have taken to protect their
information are sufficient to meet the first prong of the DTSA. The district court noted that
DHHS places significant limitations on who has access to the requested records and privatizes
the information that is shared, and that manufacturers and PBMs have submitted requests for
confidentiality to prevent the release of their trade secrets. Even Borneman's declaration added
support, stating that Sanofi restricts access to pricing information and rationale using need-toknow basis and nondisclosure agreements. These confidentiality provisions are sufficient to
constitute "reasonable measures" at preserving the information's secrecy under the DTSA.15
The Court denied TNIs argument that manufacturers and PBMs have waived any trade
secret protections they may have had by voluntarily submitting the requested documents to
DHHS. TNI’s argument relied on Amgen.16 The Court did not buy this argument, however, and
made a point to distinguish California law from Nevada law. The Court held that it is
fundamentally unfair to conclude that a manufacturer or PBM waives its trade secret protections
in the requested records by submitting them to DHHS pursuant to S.B. 539—a mandate it is
powerless to ignore.17 Therefore, because manufacturers and PBMs turned over these documents
with the expectation of confidentiality, such disclosure is not inconsistent with the determination
that the company has taken "reasonable measures" to keep the information secret with respect to
the DTSA.18
Next, the Court considered the second element of the DTSA's trade secret test: whether
the owner derives economic value from the information's nondisclosure and whether the
information is not "readily ascertainable through proper means" by an entity that can obtain
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economic benefit from the information's disclosure.19 The Court held that the district court was
within its discretion to conclude that the requested records, which identified "drug cost structure,
marketing and advertising costs, rebate strategies, and profit information," comprised trade
secrets under the DTSA because the manufacturers and PBMs "derive[ ] independent economic
value . . . from [this information] not being generally known."20 Thus, the Court concluded that
the district court appropriately determined that manufacturers and PBMs gain an economic
benefit by keeping the requested documents confidential from their competitors and the public.
As the Court has noted before, "The obligation to disclose . . . is not without limits."21
Since the documents are declared by law (i.e., the DTSA) to be confidential trade secrets, the
Court concluded that they are exempt from disclosure under the NPRA.22 Therefore, the Court
concluded that the district court's denial of the writ petition was within its discretion. DHHS
demonstrated that the requested records satisfy the DTSA's twostep test for confidentiality by
showing that manufacturers and PBMs have taken reasonable measures to shield the requested
records from disclosure and that these entities derive economic value from the requested records'
secrecy.
Conclusion:
The NPRA permits the disclosure of government documents that are not declared by law
to be confidential. In this opinion, the Court held that the requested documents are confidential
under the DTSA and are thus exempted from disclosure under the NPRA. The Court also
determined that TNI has not demonstrated that NAC 439.730-.740 are invalid regulations and
that the district court reached the correct outcome in admitting James Borneman's declaration.
For these reasons, district court's judgment is affirmed.
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